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Most common breast cancer susceptibility variants have been identified 749 
through genome-wide association studies (GWASs) of predominantly estrogen 750 
receptor (ER)-positive disease. We conducted a GWAS using 21,468 ER-751 
negative cases and 100,594 controls combined with 18,908 BRCA1 mutation 752 
carriers (9,414 with breast cancer), all of European origin. We identified 753 
independent associations at P<5x10-8 with 10 variants at nine novel loci. At 754 
P<0.05, we replicated associations with 10 of 11 variants previously reported in 755 
ER-negative or BRCA1 mutation carrier GWASs, and confirmed ER-negative 756 
disease associations for 105 susceptibility variants identified by other breast 757 
cancer GWASs. These 125 variants explain approximately 16% of the familial 758 
risk of this breast cancer subtype. There was high genetic correlation (0.72) 759 
between risk of ER-negative breast cancer and breast cancer risk for BRCA1 760 
carriers. These findings will lead to improved risk prediction and inform further 761 
fine-mapping and functional work to better understand the biological basis of 762 
ER-negative breast cancer.  763 
GWASs have identified 107 single nucleotide polymorphisms (SNPs) that are 764 
independently associated with breast cancer risk1-31. Association studies focused on 765 
ER-negative disease, or BRCA1 mutation carriers, who are more likely to develop 766 
ER-negative disease (70-80% of cases)32, have identified 11 of these 767 
SNPs2,8,11,18,28,29. We aimed to discover additional ER-negative breast cancer 768 
susceptibility variants by performing a GWAS in women of European origin. 769 
New genotyping data were generated for 9,655 ER-negative cases and 45,494 770 
controls from 68 Breast Cancer Association Consortium (BCAC) studies and 15,566 771 
BRCA1 mutation carriers (7,784 with breast cancer) from 58 Consortium of 772 
Investigators of Modifiers of BRCA1/2 (CIMBA) studies (Supplementary Tables 1 773 
and 2) using the Illumina OncoArray beadchip, a 570K SNP custom array with 774 
genome-wide coverage33. Imputation was used to derive estimated genotypes for 775 
~21M SNPs, using the 1000 Genomes Project (Phase 3) as reference; ~11.5M of 776 
those with imputation r2>0.3 and minor allele frequency (MAF)>0.005 were included 777 
in further analyses. For BCAC data, we estimated per-allele odds ratios (ORs) using 778 
logistic regression, adjusting for country and principal components. For CIMBA data, 779 
we estimated per-allele hazard ratios (HR) using a retrospective cohort analysis 780 
framework, modelling time to breast cancer and stratifying on country, Ashkenazi 781 
Jewish origin and birth cohort (see Online Methods). These analyses were also 782 
applied to an independent set of previously generated data from other genome-wide 783 
genotyping of additional European participants in 44 BCAC studies (11,813 ER-784 
negative cases and 55,100 controls) and 54 CIMBA studies (3,342 BRCA1 mutation 785 
carriers, 1,630 with breast cancer) (Supplementary Tables 1 and 2). Fixed-effects 786 
meta-analysis was used to combine results across genotyping initiatives within 787 
consortia and, assuming that the OR and HR estimates approximate the same 788 
underlying relative risk, across consortia.   789 
Results from the combined meta-analysis are summarised in Supplementary Figure 790 
1. There was minimal inflation of test statistics (lambda1000=1.004; Supplementary 791 
Figure 2). We identified 10 variants at nine novel loci that were independently 792 
associated with risk of ER-negative breast cancer at P<5x10-8 (Table 1; 793 
Supplementary Table 3; Supplementary Figures 3-10). Two independent signals 794 
were observed within 12kb at 11q22.3, for rs74911261 (MAF=0.02) and rs11374964 795 
(MAF=0.42); OR estimates and statistical significance were largely unchanged when 796 
each variant was adjusted for the other (Supplementary Table 4). The association 797 
with 8p23.3-rs66823261 was not observed for BRCA1 mutation carriers (P=0.32, P-798 
heterogeneity=0.030).   799 
For each of these 10 novel signals, we identified candidate causal SNPs analytically 800 
(see Online Methods) and combined multiple sources of in silico functional 801 
annotation from public databases to identify likely functional variants and target 802 
genes. Results are summarised in Supplementary Table 5 (including UCSC Genome 803 
Browser links; see also Supplementary Note 1), Figure 1 and Supplementary Figures 804 
3-10 (data sources in Supplementary Table 6). Many candidate causal SNPs lie in 805 
predicted regulatory regions and are associated with expression of nearby genes in 806 
blood or other tissues. At 2p23, the predicted target genes include ADCY3 and 807 
NCOA1 (Supplementary Figure 3). At 6q23.1 (Supplementary Figure 4), the most 808 
plausible target gene is L3MBTL334. A predicted target at 8q24.13 is FBXO32, which 809 
is expressed in ER-negative HMECs but not ER-positive MCF7 breast cancer cells 810 
(Supplementary Figure 6) and has a known role in cancer cachexia35. At 11q22.3 811 
(Figure 1), a predicted target gene of common risk-associated variants is NPAT36. 812 
The rarer SNPs underlying the other 11q22.3 signal are predicted to target ATM, a 813 
known breast cancer susceptibility gene37. Three rare coding variants (MAF≤0.03) in 814 
ATM, NPAT and KDELC2, are also among the candidate causal SNPs at this locus. 815 
At 16p13, predicted target genes include ADCY9 and CREBBP (Supplementary 816 
Figure 7). At 19q12 (Supplementary Figure 10), a potential target gene encodes 817 
cyclin E1 which is involved in cell cycle control and phosphorylation of NPAT38. 818 
Expression QTL associations were assessed between each candidate causal variant 819 
and genes within 1Mb using 79 ER-negative breast tumours from TCGA and 135 820 
normal breast tissue samples from METABRIC39-41. The strongest associations 821 
identified were 6q23.1-rs6569648-L3MBTL3 (P=4.3x10-6) and 18q12.1-rs12965632-822 
CDH2 (P=1.0x10-4), both in METABRIC (Supplementary Table 5). SNP rs6569648 823 
was the top cis-eQTL (of all imputed variants within 1 Mb) for L3MBTL3 while the p-824 
value for the rs12965632-CDH2 eQTL was within two orders of magnitude of the top 825 
cis-eQTLs for this gene (Supplementary Figures 11-12). 826 
For 10 of the 11 variants previously identified through GWASs of ER-negative 827 
disease or overall disease in BRCA1 mutation carriers2,8,11,17,18,29,30, or reported as 828 
more strongly associated with ER-negative breast cancer28, associations with ER-829 
negative disease were replicated (P<0.05) using OncoArray data from BCAC, which 830 
does not overlap with any of the discovery studies (Table 2). Effect sizes were 831 
generally similar to those originally reported. Using all available CIMBA data, six of 832 
these 11 variants were associated with breast cancer risk (P<0.05) for BRCA1 833 
mutation carriers (Table 2). No evidence of association was observed for 20q11-834 
rs228437811 in either BCAC or CIMBA (P≥0.46).  835 
Based on estimated ORs using BCAC data for all cases with known ER status 836 
(16,988 ER-negative; 65,275 ER-positive), all 10 new and 10 previously reported 837 
and replicated ER-negative disease susceptibility SNPs were more strongly 838 
associated with risk of ER-negative than ER-positive subtype (P-heterogeneity<0.05, 839 
except for novel hit 19p13.2-rs322144; Supplementary Table 7). Two variants 840 
(1q32.1-rs4245739 and 19p13.11-rs67397200) were not associated with ER-positive 841 
disease. For four variants (11q22.3- rs11374964, 11q22.3-rs74911261, 1q32.1-842 
rs6678914 and 2p23.2-rs4577244), the risk-associated allele for ER-negative 843 
disease was associated with reduced risk of ER-positive disease (P<0.05).  844 
For these 20 ER-negative breast cancer susceptibility SNPs, we also assessed 845 
associations by triple-negative (TN) status (negative for ER, progesterone receptor 846 
and HER2; Table 3), tumour grade (Table 4) and age at diagnosis (Supplementary 847 
Table 8) using BCAC data only. Five, including the novel susceptibility variants 848 
11q22.3-rs11374964 and 11q22.3-rs74911261, were more strongly associated with 849 
risk of both TN and higher-grade disease (P<0.05), although after adjustment for TN 850 
status, heterogeneity by grade was observed only for 11q22.3-rs74911261 and 851 
1q32.1-rs4245739 (P<0.05). For 2p23.3-rs4577244, heterogeneity was observed for 852 
grade only, while 6q25.2-rs2747652 was more strongly associated with risk of other 853 
(non-TN) ER-negative breast cancer subtypes (P<0.05). At younger ages, 854 
associations appeared to be stronger for two variants (5p15.33-rs10069690 and 855 
19p13.11-rs67397200), and weaker for one (6q25.2-rs2747652) (P<0.05).  856 
Elsewhere we report 65 novel susceptibility loci for overall breast cancer42. Three of 857 
these overlap within 500kb with the novel ER-negative disease-associated loci 858 
reported here (variants 2p23.3-rs200648189, 6q23.1-rs6569648 and 8q24.13-859 
rs17350191). We assessed associations with risk of ER-negative disease, and with 860 
risk of overall breast cancer for BRCA1 mutation carriers, for SNPs at the remaining 861 
62 loci, as well as for the 96 previously reported breast cancer susceptibility variants 862 
that were not ER-negative specific. Of these 158 SNPs, 105 were associated 863 
(P<0.05) with risk of ER-negative breast cancer, and 24 with risk for BRCA1 864 
mutation carriers (Supplementary Tables 9-10). Results for BRCA2 mutation carriers 865 
are presented in Supplementary Table 11. 866 
Pathway analysis based on mapping each SNP to the nearest gene was performed 867 
using summary association statistics from the meta-analysis of BCAC and CIMBA 868 
data combined (see Online Methods). This identified several pathways implicated in 869 
ER-negative disease (enrichment score [ES]>0.4086; Supplementary Figure 13; 870 
Supplementary Tables 12-13), including a subset that was not enriched in 871 
susceptibility to ER-positive disease (ES<0; Supplementary Table 14). One of the 872 
latter subsets was the adenylate cyclase (AC) activating pathway (ES=0.62; 873 
Supplementary Figure 14). Two of the predicted target genes for the 10 novel ER-874 
negative breast cancer susceptibility variants, based on the eQTL analysis 875 
(Supplementary Table 5), ADCY3 (P[TCGA]=6.7x10-3] and ADCY9 876 
(P[METABRIC]=1.3x10-4), are part of this pathway, and their association signals 877 
were critical to the elevated ES observed (Supplementary Figure 13). ADCY9 is 878 
stimulated by β2 adrenergic receptor (β2AR) signalling43 in ER-negative breast 879 
cancer44, which in turn drives AC-cAMP signalling, including for example mitogenic 880 
signalling through β-arrestin-Src-ERK45.  881 
 882 
To further explore the functional properties of the genome that contribute to ER-883 
negative breast cancer heritability, we conducted a partitioned heritability analysis 884 
using linkage disequilibrium (LD) score regression46. Considering 52 “baseline” 885 
genomic features, we observed the greatest enrichment for super-enhancers (2.5-886 
fold, p=2x10-7) and the H3K4me3 histone mark (2.4-fold, p=0.0005), with 33% 887 
depletion (p=0.0002) observed for repressed regions (Supplementary Table 15). No 888 
differences in enrichment for these features were observed between susceptibility to 889 
ER-negative and ER-positive breast cancer, but baseline genomic features are not 890 
specific to cell type46. The estimated correlation between ER-negative and ER-891 
positive breast cancer based on ~1M common genetic variants47 was 0.60 (standard 892 
error [SE], 0.03) indicating that, although these two breast cancer subtypes have a 893 
shared genetic component, a substantial proportion is distinct. The estimated 894 
correlation between ER-negative disease in the general population and overall 895 
breast cancer for BRCA1 mutation carriers was 0.72 (SE, 0.11). 896 
 897 
In summary, in this study of women of European origin, we have identified 10 novel 898 
susceptibility variants for ER-negative breast cancer and replicated associations with 899 
ER-negative disease for 10 SNPs identified by previous GWASs. Most of these were 900 
not associated, or more weakly associated, with ER-positive disease, consistent with 901 
the findings from pathway and partitioned heritability analyses showing that ER-902 
negative breast cancer has a partly distinct genetic aetiology. We also confirmed 903 
associations with ER-negative disease for a further 105 susceptibility SNPs. 904 
Together, these 125 variants explain ~14% of an assumed 2-fold increased risk of 905 
developing ER-negative disease for the first degree female relatives of women 906 
affected with this subtype (the newly identified SNPs explain ~1.5%); Supplementary 907 
Table 16) and ~40% of the estimated familial risk that is attributable to all variants 908 
imputable from the Oncoarray (see Online Methods). We have also identified nine 909 
novel breast cancer susceptibility variants for BRCA1 mutation carriers and 910 
confirmed associations for a further 30 previously reported SNPs; these 39 variants 911 
explain ~8% of the variance in polygenic risk for carriers of these mutations 912 
(Supplementary Table 17). However, the lower number of BRCA1 risk-associated 913 
variants may merely be a consequence of the smaller sample size, since the genetic 914 
correlation with ER-negative breast cancer is high. These findings will inform 915 
improved risk prediction, both for the general population and for BRCA1 mutation 916 
carriers29,48,49. Further investigation is required for other populations of non-917 
European origin. Fine-mapping and functional studies should lead to a better 918 
understanding of the biological basis of ER-negative breast cancer, and perhaps 919 
inform the design of more effective preventive interventions, early detection and 920 
treatments for this disease. 921 
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Table 1: Ten novel loci associated with risk of estrogen receptor (ER)-negative breast cancer using meta-analysis of BCAC and 1156 
CIMBA data 1157 
 
Location 
 
SNP 
 
Chr 
 
Position Nearest gene 
 
Alleles# 
 
BCAC ER-negative†  
 
CIMBA BRCA1 mutation carriersǂ  
 
Meta-analysis 
 
     P-value 
 
Heterogeneity 
 
  P-value¥ 
 
MAF 
 
OR (95%CI) 
 
P-value  
 
MAF 
 
HR (95%CI) 
 
P-value  
2p23.3 rs200648189   2 24739694 NCOA1 CT/C 0.19 0.94 (0.91-0.97) 4.7x10-4  0.20 0.88 (0.84-0.92) 3.3x10-7  9.7x10-9    2.0x10-2 
6q23.1 rs6569648   6 130349119 L3MBTL3 T/C 0.23 0.93 (0.90-0.95) 4.3x10-8  0.22 0.94 (0.90-0.98) 5.4x10-3  8.3x10-10 0.64 
8p23.3 rs66823261   8 170692 RPL23AP53 T/C 0.23 1.09 (1.06-1.12) 5.6x10-9  0.22 1.02 (0.98-1.07)    0.32  3.3x10-8    3.0x10-2 
8q24.13 rs17350191   8 124757661 ANXA13 C/T 0.34 1.07 (1.04-1.09) 2.0x10-8  0.34 1.08 (1.04-1.12) 1.9x10-4  1.7x10-11 0.81 
11q22.3 rs11374964  11 108345515 KDELC2 G/GA 0.42 0.94 (0.92-0.96) 3.6x10-8  0.43 0.91 (0.88-0.95) 1.3x10-6  4.1x10-13 0.26 
11q22.3 rs74911261 11 108357137 KDELC2 G/A 0.02 0.82 (0.75-0.89) 2.3x10-6  0.02 0.74 (0.65-0.84) 2.0x10-6  5.4x10-11 0.17 
16p13.3 rs11076805 16 4106788 ADCY9 C/A 0.25 0.92 (0.90-0.95) 2.2x10-8  0.25 0.96 (0.92-1.00)   0.073  1.4x10-8 0.14 
18q12.1 rs36194942 18 25401204 CDH2 A/AT 0.30 0.94 (0.91-0.96) 2.5x10-7  0.31 0.95 (0.91-0.99) 1.4x10-2  1.4x10-8 0.50 
19p13.2 rs322144 19 11423703 TSPAN16 C/G 0.47 0.95 (0.93-0.97) 2.4x10-5  0.46 0.92 (0.89-0.96) 3.7x10-5  7.4x10-9 0.23 
19q12 rs113701136 19 30277729 CCNE1 C/T 0.32 1.07 (1.04-1.09) 1.7x10-7  0.32 1.05 (1.01-1.09) 1.2x10-2  6.8x10-9 0.57 
 1158 
#More common allele listed first, minor allele second; †Combined data from 21,468 ER-negative cases and 100,594 controls of European ancestry from the Breast Cancer Association Consortium 1159 
(BCAC); ǂCombined data from 18,908 BRCA1 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), 9,414 of whom had developed breast cancer; ¥Test for 1160 
heterogeneity in effect size for ER-negative disease and overall disease for BRCA1 mutation carriers 1161 
Chr, chromosome; MAF, minor allele frequency; OR, odds ratio per copy of the minor allele; CI, confidence interval; HR, hazard ratio per copy of the minor allele 1162 
 1163 
 1164 
  1165 
Table 2: Previously reported estrogen receptor (ER)-negative hits: replication using independent data from BCAC and combined 1166 
results using all BCAC and CIMBA data 1167 
 
 
Location 
 
 
SNP 
 
 
Chr 
 
 
Position 
 
Ref 
 
Nearest 
gene 
 
Alleles# 
 
INDEPENDENT REPLICATION  
 
ALL AVAILABLE DATA COMBINED 
 
BCAC ER-negative (OncoArray)*   
 
BCAC ER-negative†  
 
CIMBA BRCA1ǂ 
 
MAF 
 
OR (95%CI) 
 
P-value 
   
OR (95%CI) 
 
P-value 
  
HR (95%CI) 
 
P-value 
1q32.1 rs6678914   1 202187176 18 LGR6 G/A 0.41 0.94 (0.91-0.97) 1.1x10-4   0.92 (0.90-0.94) 2.6x10-12  0.98 (0.95-1.02)    0.31 
1q32.1 rs4245739   1 204518842 18 MDM4 A/C 0.26 1.12 (1.09-1.17) 9.2x10-11   1.14 (1.11-1.16) 3.1x10-23  1.09 (1.04-1.13) 7.3x10-5 
2p24.1 rs12710696   2 19320803 18 MIR4757 C/T 0.37 1.04 (1.00-1.07) 2.5x10-2   1.06 (1.04-1.09) 6.5x10-8  1.01 (0.98-1.05)    0.49 
2p23.2 rs4577244ǂ   2 29120733 29 WDR43 C/T 0.34 0.93 (0.89-0.96) 9.6x10-5   0.92 (0.90-0.95) 1.5x10-9  0.92 (0.88-0.96) 1.3x10-4 
5p15.33 rs10069690    5 1279790 8,17 TERT C/T 0.26 1.19 (1.14-1.23) 3.8x10-21   1.18 (1.15-1.21) 1.5x10-35  1.18 (1.14-1.23) 3.7x10-16 
6q25.1 rs3757322ǂ   6 151942194 28 ESR1 T/G 0.32 1.14 (1.10-1.18) 5.5x10-14   1.15 (1.12-1.18) 2.8x10-31  1.14 (1.10-1.19) 2.9x10-12 
6q25.2 rs2747652ǂ   6 152437016 28 ESR1 C/T 0.48 0.92 (0.89-0.95) 1.1x10-7   0.91 (0.89-0.93) 1.9x10-18  1.00 (0.97-1.04)    0.96 
13q22.1 rs6562760ǂ 13 73957681 29 KLF5 G/A 0.24 0.92 (0.88-0.95) 5.0x10-6   0.92 (0.90-0.95) 8.7x10-10  0.89 (0.86-0.93) 3.5x10-7 
16q12.2 rs11075995 16 53855291 18 FTO T/A 0.30 1.07 (1.03-1.11) 3.3x10-4   1.09 (1.06-1.12) 1.0x10-10  1.01 (0.97-1.06)    0.49 
19p13.11 rs67397200 19 17401404 2,30 ANKLE1 C/G 0.32 1.17 (1.13-1.21) 7.0x10-20   1.17 (1.14-1.19) 2.7x10-37  1.18 (1.14-1.23) 2.7x10-17 
20q11.21 rs2284378  20 32588095 11 RALY C/T 0.32 0.99 (0.95-1.02)    0.46   1.03 (1.01-1.06) 1.7x10-2  1.00 (0.97-1.04)    0.81 
 1168 
#More common allele listed first, minor allele second; *Includes Breast Cancer Association Consortium (BCAC) OncoArray data from 9,655 ER-negative cases and 45,494 controls cases and 1169 
controls not included in previously published studies; †Combined data from 21,468 ER-negative cases and 100,594 controls of European ancestry from BCAC, which includes overlapping samples 1170 
with previous publications for all SNPs; ǂCombined data from 18,908 BRCA1 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), 9,414 of whom had developed 1171 
breast cancer - includes overlapping samples with previous publications for SNPs rs4577244, rs3757322, rs2747652 and rs6562760 1172 
Chr, chromosome; Ref, publication(s) in reference list in which the association was identified; MAF, minor allele frequency; OR, odds ratio per copy of the minor allele; CI, confidence interval; HR, 1173 
hazard ratio per copy of the minor allele 1174 
 1175 
  1176 
Table 3: Associations for 10 novel and 10 previously reported (and replicated) ER- 1177 
negative breast cancer susceptibility loci, by triple-negative status  1178 
(BCAC data only: ER-negative casesǂ, all controls)) 1179 
 
Location 
 
SNP 
 
Triple-negative  
 
Other ER-negative 
 
Heterogeneity 
 
OR (95%CI) 
 
P-value  
 
OR (95%CI) 
 
P-value 
 
P-value* 
Loci identified by the present study     
2p23.3 rs200648189 0.95 (0.90-1.00) 4.8x10-2  0.96 (0.91-1.03)    0.24 0.36 
6q23.1 rs6569648 0.93 (0.89-0.97) 1.4x10-3  0.93 (0.88-0.98) 5.6x10-3 0.91 
8p23.3 rs66823261 1.11 (1.05-1.16) 3.3x10-5  1.12 (1.07-1.19) 2.4x10-5 0.91 
8q24.13 rs17350191 1.07 (1.03-1.11) 7.9x10-4  1.07 (1.02-1.12) 4.0x10-3 0.67 
11q22.3 rs11374964  0.88 (0.85-0.91) 1.9x10-11  0.99 (0.95-1.04)    0.75 1.5x10-5 
11q22.3 rs74911261 0.76 (0.66-0.87) 1.1x10-4  0.98 (0.84-1.13)    0.76 3.0x10-2 
16p13.3 rs11076805 0.91 (0.87-0.96) 1.5x10-4  0.95 (0.90-1.00) 4.5x10-2 0.20 
18q12.1 rs36194942 0.93 (0.89-0.96) 2.4x10-4  0.92 (0.88-0.97) 9.9x10-4 0.94 
19p13.2 rs322144 0.94 (0.91-0.98) 5.9x10-3  0.94 (0.90-0.98) 9.7x10-3 0.68 
19q12 rs113701136 1.10 (1.06-1.15) 9.1x10-7  1.07 (1.02-1.12) 4.4x10-3 0.12 
Previously reported loci (associations replicated by the present study) 
1q32.1 rs6678914 0.94 (0.91-0.98) 2.1x10-3  0.91 (0.87-0.95) 2.0x10-5 0.45 
1q32.1 rs4245739 1.18 (1.13-1.23) 4.3x10-15  1.04 (1.00-1.10) 7.5x10-2 6.5x10-4 
2p24.1 rs12710696 1.07 (1.03-1.11) 1.1x10-3  1.04 (1.00-1.09) 6.1x10-2 0.52 
2p23.2 rs4577244 0.90 (0.86-0.94) 5.3x10-6  0.94 (0.89-0.99) 1.9x10-2 0.15 
5p15.33 rs10069690  1.28 (1.23-1.33) 2.4x10-33  1.07 (1.02-1.12) 5.4x10-3 5.6x10-8 
6q25.1 rs3757322 1.15(1.10-1.19) 4.3x10-12  1.14(1.10-1.20)  4.8x10-9 0.35 
6q25.2 rs2747652 0.93(0.89-0.96) 5.7x10-5  0.87(0.83-0.91)  2.9x10-10 9.6x10-3 
13q22.1 rs6562760 0.94 (0.90-0.98) 2.8x10-3  0.92 (0.87-0.96) 8.8x10-4 0.46 
16q12.2 rs11075995 1.06 (1.02-1.11) 6.5x10-3  1.08 (1.03-1.13) 3.1x10-3 0.81 
19p13.11 rs67397200 1.27 (1.22-1.32) 2.0x10-32  1.05 (1.01-1.10) 2.7x10-2 4.7x10-10 
 1180 ǂCombined Breast Cancer Association Consortium (BCAC) data from 6,877 triple-negative and 4,467 other ER-negative cases  1181 
and 83,700 controls; *ER-negative case-only analysis, by triple-negative status; OR, odds ratio per copy of the minor allele;  1182 
CI, confidence interval 1183 
 1184 
 1185 
  1186 
Table 4: Associations for 10 novel and 10 previously reported (and replicated) ER-negative breast cancer  1187 
susceptibility loci, by grade (BCAC data only: ER-negative casesǂ, all controls) 1188 
 
Location 
 
SNP 
 
Grade 1  
 
Grade 2  
 
Grade 3 
 
Heterogeneity 
 
P-value* 
 
OR (95%CI) 
 
P-value  
 
OR (95%CI) 
 
P-value 
  
OR (95%CI) 
 
P-value 
Loci identified by the present study        
2p23.3 rs200648189 1.11 (0.92-1.33)    0.28  0.95 (0.88-1.03)    0.23  0.96 (0.91-1.00) 6.8x10-2    0.70 
6q23.1 rs6569648 0.93 (0.79-1.09)    0.37  0.93 (0.87-0.99) 1.6x10-2  0.94 (0.91-0.98) 3.8x10-3    0.34 
8p23.3 rs66823261 1.13 (0.96-1.34)    0.14  1.12 (1.04-1.19) 1.2x10-3  1.10 (1.05-1.15) 1.3x10-5    0.11 
8q24.13 rs17350191 1.16 (1.01-1.34) 3.0x10-2  1.05 (0.99-1.11)    0.10  1.09 (1.05-1.12) 4.1x10-6    0.94 
11q22.3 rs11374964  0.91 (0.79-1.04)    0.16  0.99 (0.94-1.05)    0.85  0.93 (0.90-0.96) 1.3x10-5 3.0x10-2 
11q22.3 rs74911261 1.22 (0.81-1.84)    0.35  0.89 (0.73-1.07)    0.21  0.74 (0.65-0.85) 7.4x10-6 6.7x10-4 
16p13.3 rs11076805 0.90 (0.76-1.06)    0.21  0.93 (0.87-0.99) 3.2x10-2  0.92 (0.88-0.95) 4.5x10-5    0.71 
18q12.1 rs36194942 0.97 (0.84-1.13)    0.73  0.93 (0.88-0.99) 2.2x10-2  0.96 (0.92-0.99) 2.3x10-2    0.98 
19p13.2 rs322144 0.94 (0.81-1.08)    0.38  0.95 (0.90-1.01)    0.11  0.96 (0.93-1.00) 6.4x10-2    0.48 
19q12 rs113701136 1.02 (0.89-1.18)    0.77  1.06 (1.01-1.13) 3.0x10-2  1.10 (1.06-1.14) 2.5x10-7    0.12 
Previously reported loci (associations replicated by the present study)    
1q32.1 rs6678914 0.95 (0.83-1.09)    0.46  0.90 (0.85-0.95) 9.3x10-5  0.92 (0.89-0.95) 1.2x10-6     0.75 
1q32.1 rs4245739 1.02 (0.88-1.19)    0.75  1.05 (0.99-1.12) 8.7x10-2  1.18 (1.14-1.22) 2.5x10-18 4.3x10-5 
2p24.1 rs12710696 1.08 (0.94-1.23)    0.28  1.10 (1.04-1.16) 9.6x10-4  1.04 (1.01-1.08) 1.6x10-2    0.28 
2p23.2 rs4577244 1.02 (0.88-1.20)    0.77  0.95 (0.89-1.01) 9.4x10-2  0.90 (0.86-0.93) 1.2x10-7 4.0x10-2 
5p15.33 rs10069690  0.96 (0.83-1.12)    0.64  1.07 (1.01-1.14) 2.2x10-2  1.21 (1.17-1.26) 1.5x10-24 7.3x10-4 
6q25.1 rs3757322 1.16 (1.01-1.34)    0.04  1.13 (1.07-1.20) 7.5x10-6  1.18 (1.14-1.22) 4.5x10-20    0.16 
6q25.2 rs2747652 0.86 (0.75-0.98)    0.02  0.92 (0.87-0.97) 1.9x10-3  0.90 (0.87-0.93) 1.6x10-9    0.61 
13q22.1 rs6562760 0.98 (0.84-1.15)    0.82  0.92 (0.87-0.98) 1.4x10-2  0.91 (0.88-0.95) 1.2x10-5    0.52 
16q12.2 rs11075995 1.16 (1.00-1.35) 4.7x10-2  1.09 (1.02-1.15) 7.5x10-3  1.08 (1.04-1.13) 5.2x1028    0.42 
19p13.11 rs67397200 1.01 (0.87-1.16)    0.91  1.08 (1.02-1.14) 9.8x10-3  1.22 (1.18-1.26) 5.3x10-37 1.3x10-3 
 1189 ǂCombined Breast Cancer Association Consortium (BCAC) data from 492 grade 1, 3,243 grade 2 and 8,568 grade 3 cases and 82,347 controls; * ER-negative case-only  1190 
analysis of BCAC data, by grade (trend test, 1df); OR, odds ratio per copy of the minor allele; CI, confidence interval 1191 
Figure legends 1192 
Figure 1. Genomic region around the two independent ER negative risk 1193 
associated variants, 11_108345515_G_A (rs11374964) and 11_108357137_G_A 1194 
(rs74911261). One Mb region showing statistical significance of all genotyped and 1195 
imputed SNPs (regional Manhattan plot) and positions of candidate causal variants 1196 
for two independent signals (shown as red or blue tick marks) in relation to RefSeq 1197 
annotated genes. Missense variants are labelled with asterisks. Breast cell 1198 
enhancers overlapping candidate SNPs predicted to target nearby genes by IM-PET 1199 
(He et al., PNAS 2014) are depicted as black bars. Chromatin interactions from 1200 
ENCODE ChIA-PET experiments in MCF7 cells overlapping candidate variants are 1201 
depicted as boxes connected by thin lines and shaded to reflect the confidence 1202 
score of the interaction. Epigenomic features (derived from publicly available 1203 
transcription factor ChIP-seq, histone modification ChIP-seq and DNase 1204 
hypersensitive site-seq) that overlap candidate variants are shown as red or blue 1205 
segments, depending on the signal which is intersected. Density tracks show the 1206 
summed occurrence of transcription factor ChIP-seq, histone modification ChIP-seq, 1207 
and DNase hypersensitive site peaks at each genomic position. Roadmap 1208 
Epigenomics Project chromatin state models for HMEC and myoepithelial cells 1209 
grouped into enhancer, promoter or transcribed annotations are shown as yellow, 1210 
red or green segments, respectively. Transcript levels in MCF7 and HMEC cells are 1211 
represented by histograms depicting the mean of combined and normalised RNA-1212 
seq expression level at each genomic position. All MCF7 ChIA-PET (ENCODE) and 1213 
HMEC Hi-C (Rao et al., Cell 2014) chromatin interactions are represented by black 1214 
and blue arcs, respectively. Published GWAS signals from the NHGRI catalog are 1215 
shown as green ticks. The last track shows tested Oncoarray SNPs (genotyped or 1216 
imputed) as black ticks and uninterrogated, common (dbSNP 138 EUR MAF > 1%) 1217 
SNPs as red ticks. Supplementary Table 5 provides full details of functional 1218 
annotation for each risk locus including a link to the UCSC Genome Browser, which 1219 
allows these features to be examined in more detail. 1220 
  1221 
Supplementary Figure 1. Manhattan plot of associations with breast cancer 1222 
risk for all imputed and genotyped SNPs using combined data from ER-1223 
negative cases and controls and BRCA1 mutation carriers, before (A) and after 1224 
(B) excluding known breast cancer susceptibility loci. 1225 
Supplementary Figure 2. Quantile-quantile plot of associations with breast 1226 
cancer risk for all imputed and genotyped SNPs using combined data from ER-1227 
negative cases and controls and BRCA1 mutation carriers. 1228 
Supplementary Figure 3. Genomic region around the ER negative risk 1229 
associated variant 2_24739694_CT_T (rs200648189). One Mb region showing 1230 
statistical significance of all genotyped and imputed SNPs (regional Manhattan plot) 1231 
and positions of candidate causal variants in relation to RefSeq annotated genes. 1232 
Breast cell enhancers overlapping candidate SNPs predicted to target nearby genes 1233 
by methods including IM-PET50 and Hnisz51 are depicted as black bars. Chromatin 1234 
interactions from ENCODE ChIA-PET experiments in MCF7 cells overlapping 1235 
candidate variants are depicted as boxes connected by thin lines and shaded to 1236 
reflect the confidence score of the interaction. Epigenomic features (derived from 1237 
publicly available transcription factor ChIP-seq, histone modification ChIP-seq and 1238 
DNase hypersensitive site-seq) that overlap candidate variants are shown as red 1239 
segments. Density tracks show the summed occurrence of transcription factor ChIP-1240 
seq, histone modification ChIP-seq, and DNase hypersensitive site peaks at each 1241 
genomic position. Roadmap Epigenomics Project chromatin state models for HMEC 1242 
and myoepithelial cells grouped into enhancer, promoter or transcribed annotations 1243 
are shown as yellow, red or green segments, respectively. Transcript levels in MCF7 1244 
and HMEC cells are represented by histograms depicting the mean of combined and 1245 
normalised RNA-seq expression level at each genomic position. All MCF7 ChIA-PET 1246 
(ENCODE) chromatin interactions are represented by black arcs. Published GWAS 1247 
signals from the NHGRI catalog are shown as green ticks. The last track shows 1248 
tested Oncoarray SNPs (genotyped or imputed) as black ticks and uninterrogated, 1249 
common (dbSNP 138 EUR MAF>1%) SNPs as red ticks. 1250 
Supplementary Figure 4. Genomic region around the ER negative risk 1251 
associated variant 6_130349119_T_C (rs6569648). One Mb region showing 1252 
statistical significance of all genotyped and imputed SNPs (regional Manhattan plot) 1253 
and positions of candidate causal variants in relation to RefSeq annotated genes. 1254 
Chromatin interactions from ENCODE ChIA-PET experiments in MCF7 cells 1255 
overlapping candidate variants are depicted as boxes connected by thin lines and 1256 
shaded to reflect the confidence score of the interaction. Epigenomic features 1257 
(derived from publicly available transcription factor ChIP-seq and histone 1258 
modification ChIP-seq) which overlap candidate variants are shown as red 1259 
segments. Density tracks show the summed occurrence of transcription factor ChIP-1260 
seq, histone modification ChIP-seq, and DNase hypersensitive site peaks at each 1261 
genomic position. Roadmap Epigenomics Project chromatin state models for HMEC 1262 
and myoepithelial cells grouped into enhancer, promoter or transcribed annotations 1263 
are shown as yellow, red or green segments, respectively. Transcript levels in MCF7 1264 
and HMEC cells are represented by histograms depicting the mean of combined and 1265 
normalised RNA-seq expression level at each genomic position. All MCF7 ChIA-PET 1266 
(ENCODE) and HMEC Hi-C52 chromatin interactions are represented by black and 1267 
blue arcs, respectively. Published GWAS signals from the NHGRI catalog are shown 1268 
as green ticks. The last track shows tested Oncoarray SNPs (genotyped or imputed) 1269 
as black ticks and uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as 1270 
red ticks. 1271 
Supplementary Figure 5. Genomic region around the ER negative risk 1272 
associated variant 8_170692_T_C (rs66823261). One Mb region showing 1273 
statistical significance of all genotyped and imputed SNPs (regional Manhattan plot) 1274 
and positions of candidate causal variants in relation to RefSeq annotated genes. 1275 
Chromatin interactions from ENCODE ChIA-PET experiments in MCF7 cells 1276 
overlapping candidate variants are depicted as boxes connected by thin lines and 1277 
shaded to reflect the confidence score of the interaction. Epigenomic features 1278 
derived from publicly available transcription factor ChIP-seq which overlap candidate 1279 
variants are shown as red segments. Density tracks show the summed occurrence 1280 
of transcription factor ChIP-seq, histone modification ChIP-seq, and DNase 1281 
hypersensitive site peaks at each genomic position. Roadmap Epigenomics Project 1282 
chromatin state models for HMEC and myoepithelial cells grouped into enhancer, 1283 
promoter or transcribed annotations are shown as yellow, red or green segments, 1284 
respectively. Transcript levels in MCF7 and HMEC cells are represented by 1285 
histograms depicting the mean of combined and normalised RNA-seq expression 1286 
level at each genomic position . All MCF7 ChIA-PET (ENCODE) and HMEC Hi-C52 1287 
chromatin interactions are represented by black and blue arcs, respectively. 1288 
Published GWAS signals from the NHGRI catalog are shown as green ticks. The last 1289 
track shows tested Oncoarray SNPs (genotyped or imputed) as black ticks and 1290 
uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as red ticks. 1291 
Supplementary Figure 6. Genomic region around the ER negative risk 1292 
associated variant 8_124757661_C_T (rs17350191). One Mb region showing 1293 
statistical significance of all genotyped and imputed SNPs (regional Manhattan plot) 1294 
and positions of candidate causal variants in relation to RefSeq annotated genes. 1295 
Chromatin interactions from ENCODE ChIA-PET experiments in MCF7 cells 1296 
overlapping candidate variants are depicted as boxes connected by thin lines and 1297 
shaded to reflect the confidence score of the interaction. Epigenomic features 1298 
(derived from publicly available transcription factor ChIP-seq, histone modification 1299 
ChIP-seq and DNase hypersensitive site-seq) that overlap candidate variants are 1300 
shown as red segments. Density tracks show the summed occurrence of 1301 
transcription factor ChIP-seq, histone modification ChIP-seq, and DNase 1302 
hypersensitive site peaks at each genomic position. Roadmap Epigenomics Project 1303 
chromatin state models for HMEC and myoepithelial cells grouped into enhancer, 1304 
promoter or transcribed annotations are shown as yellow, red or green segments, 1305 
respectively. Transcript levels in MCF7 and HMEC cells are represented by 1306 
histograms depicting the mean of combined and normalised RNA-seq expression 1307 
level at each genomic position. All MCF7 ChIA-PET (ENCODE) and HMEC Hi-C52 1308 
chromatin interactions are represented by black and blue arcs, respectively. 1309 
Published GWAS signals from the NHGRI catalog are shown as green ticks. The last 1310 
track shows tested Oncoarray SNPs (genotyped or imputed) as black ticks and 1311 
uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as red ticks. 1312 
Supplementary Figure 7. Genomic region around the ER negative risk 1313 
associated variant 16_4106788_C_A (rs11076805). One Mb region showing 1314 
statistical significance of all genotyped and imputed SNPs (regional Manhattan plot) 1315 
and positions of candidate causal variants in relation to RefSeq annotated genes. 1316 
Breast cell enhancers overlapping candidate SNPs predicted to target nearby genes 1317 
by PreSTIGE53 are depicted as black bars. Chromatin interactions from ENCODE 1318 
ChIA-PET experiments in MCF7 cells overlapping candidate variants are depicted as 1319 
boxes connected by thin lines and shaded to reflect the confidence score of the 1320 
interaction. Epigenomic features (derived from publicly available transcription factor 1321 
ChIP-seq and  histone modification ChIP-seq) which overlap candidate variants are 1322 
shown as red segments. Density tracks show the summed occurrence of 1323 
transcription factor ChIP-seq, histone modification ChIP-seq, and DNase 1324 
hypersensitive site peaks at each genomic position. Roadmap Epigenomics Project 1325 
chromatin state models for HMEC and myoepithelial cells grouped into enhancer, 1326 
promoter or transcribed annotations are shown as yellow, red or green segments, 1327 
respectively. Transcript levels in MCF7 and HMEC cells are represented by 1328 
histograms depicting the mean of combined and normalised RNA-seq expression 1329 
level at each genomic position. All MCF7 ChIA-PET (ENCODE) and HMEC Hi-C52 1330 
chromatin interactions are represented by black and blue arcs, respectively. 1331 
Published GWAS signals from the NHGRI catalog are shown as green ticks. The last 1332 
track shows tested Oncoarray SNPs (genotyped or imputed) as black ticks and 1333 
uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as red ticks. 1334 
Supplementary Figure 8. Genomic region around the ER negative risk 1335 
associated variant 18_25401204_A_AT (rs36194942). One Mb region showing 1336 
statistical significance of all genotyped and imputed SNPs (regional Manhattan plot) 1337 
and positions of candidate causal variants in relation to RefSeq annotated genes. 1338 
Epigenomic features (derived from publicly available transcription factor ChIP-seq, 1339 
histone modification ChIP-seq and DNase hypersensitive site-seq) that overlap 1340 
candidate variants are shown as red segments. Density tracks show the summed 1341 
occurrence of transcription factor ChIP-seq, histone modification ChIP-seq, and 1342 
DNase hypersensitive site peaks at each genomic position. Roadmap Epigenomics 1343 
Project chromatin state models for HMEC and myoepithelial cells grouped into 1344 
enhancer, promoter or transcribed annotations are shown as yellow, red or green 1345 
segments, respectively. Transcript levels in MCF7 and HMEC cells are represented 1346 
by histograms depicting the mean of combined and normalised RNA-seq expression 1347 
level at each genomic position. All MCF7 ChIA-PET (ENCODE) and HMEC Hi-C52 1348 
chromatin interactions are represented by black and blue arcs, respectively. 1349 
Published GWAS signals from the NHGRI catalog are shown as green ticks. The last 1350 
track shows tested Oncoarray SNPs (genotyped or imputed) as black ticks and 1351 
uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as red ticks. 1352 
Supplementary Figure 9. Genomic region around the ER negative risk 1353 
associated variant 19_11423703_C_G (rs322144). One Mb region showing 1354 
statistical significance of all genotyped and imputed SNPs (regional Manhattan plot) 1355 
and positions of candidate causal variants in relation to RefSeq annotated genes. 1356 
Chromatin interactions from ENCODE ChIA-PET experiments in MCF7 cells 1357 
overlapping candidate variants are depicted as boxes connected by thin lines and 1358 
shaded to reflect the confidence score of the interaction. Epigenomic features 1359 
(derived from publicly available transcription factor ChIP-seq and DNase 1360 
hypersensitive site-seq) that overlap candidate variants are shown as red segments. 1361 
Density tracks show the summed occurrence of transcription factor ChIP-seq, 1362 
histone modification ChIP-seq, and DNase hypersensitive site peaks at each 1363 
genomic position. Roadmap Epigenomics Project chromatin state models for HMEC 1364 
and myoepithelial cells grouped into enhancer, promoter or transcribed annotations 1365 
are shown as yellow, red or green segments, respectively. Transcript levels in MCF7 1366 
and HMEC cells are represented by histograms depicting the mean of combined and 1367 
normalised RNA-seq expression level at each genomic position. All MCF7 ChIA-PET 1368 
(ENCODE) and HMEC Hi-C52 chromatin interactions are represented by black and 1369 
blue arcs, respectively. Published GWAS signals from the NHGRI catalog are shown 1370 
as green ticks. The last track shows tested Oncoarray SNPs (genotyped or imputed) 1371 
as black ticks and uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as 1372 
red ticks. 1373 
Supplementary Figure 10. Genomic region around the ER negative risk 1374 
associated variant 19_30277729_C_T (rs113701136). One Mb region showing 1375 
statistical significance of all genotyped and imputed SNPs (regional Manhattan plot) 1376 
and positions of candidate causal variants in relation to RefSeq annotated genes. 1377 
Chromatin interactions from ENCODE ChIA-PET experiments in MCF7 cells 1378 
overlapping candidate variants are depicted as boxes connected by thin lines and 1379 
shaded to reflect the confidence score of the interaction. Epigenomic features 1380 
(derived from publicly available transcription factor ChIP-seq, histone modification 1381 
ChIP-seq and DNase hypersensitive site-seq) that overlap candidate variants are 1382 
shown as red segments. Density tracks show the summed occurrence of 1383 
transcription factor ChIP-seq, histone modification ChIP-seq, and DNase 1384 
hypersensitive site peaks at each genomic position. Roadmap Epigenomics Project 1385 
chromatin state models for HMEC and myoepithelial cells grouped into enhancer, 1386 
promoter or transcribed annotations are shown as yellow, red or green segments, 1387 
respectively. Transcript levels in MCF7 and HMEC cells are represented by 1388 
histograms depicting the mean of combined and normalised RNA-seq expression 1389 
level at each genomic position. All MCF7 ChIA-PET (ENCODE) and HMEC Hi-C52 1390 
chromatin interactions are represented by black and blue arcs, respectively. 1391 
Published GWAS signals from the NHGRI catalog are shown as green ticks. The last 1392 
track shows tested Oncoarray SNPs (genotyped or imputed) as black ticks and 1393 
uninterrogated, common (dbSNP 138 EUR MAF>1%) SNPs as red ticks. 1394 
Supplementary Figure 11. Regional eQTL association plot for all variants 1395 
within 1 Mb of gene L3MTBL3 and expression of gene L3MTBL3.  Red dots 1396 
indicate candidate causal risk variants from the meta-analysis of BCAC ER-negative 1397 
case-control and CIMBA BRCA1 mutation carrier data. 1398 
Supplementary Figure 12. Regional eQTL association plot for all variants 1399 
within 1 Mb of gene CDH2 and expression of gene CDH2.  Red dots indicate 1400 
candidate causal risk variants from the meta-analysis of BCAC ER-negative case-1401 
control and CIMBA BRCA1 mutation carrier data. 1402 
Supplementary Figure 13. Enrichment map for pathways enriched in 1403 
susceptibility to ER-negative breast cancer.  (A) Enriched pathways (enrichment 1404 
score [ES]>0.4086) are grouped into themes and annotated with genes that 1405 
appeared to drive the enrichment signal (see Online Methods). (B) Zoom-in on the 1406 
adenylate cyclase theme. Shaded circles represent pathways (darker red indicates 1407 
higher ES and larger size denotes a greater number of genes in the pathway) and 1408 
green lines connect those that are most similar in terms of gene set overlap (>70%), 1409 
with thicker lines denoting greater similarity.  1410 
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